A simple non-separation assay for the measurement of total glycated serum protein is described. It was found that the¯uorescence intensity of a solution of a¯uorescein±boronic acid derivative was quenched in proportion to the amount of serum added. This led to the development of an assay in which 10 mL of serum is added to 4 mL of a solution of the¯uorescein±boronic acid derivative and thē uorescence intensity is measured after 15 min. The results, as measured by drop in uorescence intensity, calibrated by a single standard, were compared with the results for nitroblue tetrazolium (NBT) reduction of fructosamine and showed good correlation (r=0´936, n=114). The intra-assay precision (seven samples each measured 10 times) was less than 2´1% (concentration range 190±660 mmol/L); inter-assay precision for seven samples in 10 assays was less than 2´5% (over the same concentration range). Dilution of serum that had a high concentration of total glycated protein showed the assay to be linear. Serum samples (with low, medium and high total glycated protein concentrations) showed less than 2´1% difference from base results with added glucose (up to 60 mmol/L), less than 9´7% difference with added bilirubin (up to 250 mmol/L) and less than 6´9% with added triglycerides (up to 50 mmol/L). Addition of haemoglobin (up to 0´9 g/dL) with high glycation (11´7% HbA 1c ) to plasma (298 mmol/L total glycated protein) showed less than 10% difference from the base result. Assays performed over a range of temperatures (12± 34 Ê C) showed no signi®cant differences in the results. The assay gives similar results to the currently used NTB method but with signi®cantly less susceptibility to interferences. As such the method should be a useful aid in the management of diabetes.
INTRODUCTION
Glucose binds to proteins rapidly and reversibly to form Schiff bases. A small proportion of the Schiff base products undergoes Amadori rearrangement to form stable ketoamine adducts. The amount of ketoamine formed is proportional to the mean glucose concentration during the lifetime of the protein. The ketoamine adducts are known as glycated proteins. Total glycated serum protein (often called fructosamine) is the name given to the adducts derived from glucose and serum proteins. 1 Glycated haemoglobin or glycohaemoglobin is the name for all carbohydrate derivatives that are stably bound to haemoglobin (including HbA 1c , HbA 1 and total glycated haemoglobin). 2 Total glycated serum protein and glycated haemoglobin measurements are used as an aid in the management of diabetes. 1±3 Total glycated protein measurements give an estimate of the glycaemic control over the 1±3 weeks preceding sampling, 1, 3, 4 whereas glycated haemoglobin measurements give an estimate of glycaemic control over the preceding 8±12 weeks. 2±4 Total glycated serum protein measurements complement glycated haemoglobin measurements and are often used preferentially for patients with gestational diabetes (for which more frequent measurement is necessary), 5 for the early detection of changes in glucose control (e.g. after beginning a new course of therapy), 3, 6 for anaemic patients (e.g. those with haemolytic anaemia) 5 and for patients with abnormal haemoglobins (assays for glycated haemoglobin are often subject to interference). 7 In many clinics in the developing world, there are signi®cant numbers of patients with anaemia and abnormal haemoglobins (notably in Africa, the Caribbean and Asia), and the high cost of most glycated haemoglobin assays is an additional constraint.
To date, reduction of nitroblue tetrazolium dye (NBT) has been the most common method to estimate glycated serum protein (fructosamine). 1, 3 The method is commonly referred to as the`fructosamine' method. Other methods have been reported, including af®nity chromatography, 8¯u orescence polarization, 9¯u orescence enhancement, 10 hydrolysis to yield furosine 11 and thiobarbituric acid. 8 Assays for glycated albumin have also been developed and are interpreted in a similar manner to glycated serum protein measurements (immunoassay of glycated albumin 12 and enzyme-linked boronate immunoassay of glycated albumin 13 ). Following the successful development of a non-separation glycated haemoglobin assay using¯uorescent boronic acid derivatives, 14±16 it was found that the methodology could be applied to the measurement of total glycated serum protein.
The principle of the method is that thē uorescence of a¯uorophore, boronic acid derivative, is quenched when it is bound to glycated proteins but not when it is unbound ( Fig. 1 ). The drop in¯uorescence was found to be proportional to the concentration of glycated protein. Previous publications of the methodology described the development of non-separa-tion¯uorescence assays for the estimation of glycated haemoglobin. 14±16 During the development of these assays it was found that ā uorescein compound showed dose-responsive quenching with glycated serum proteins. 17 This paper describes the¯uorescence quenching of a¯uorescein±boronic acid derivative with glycated serum protein (fructosamine) and the performance of a simple non-separation method for the measurement of total glycated serum protein. Assay results are compared with those of the NBT reduction method for fructosamine.
MATERIALS AND METHODS

Patients' samples
One hundred and fourteen serum samples from diabetic patients were selected to give a range of total glycated serum protein concentrations. Following the NBT assay the samples were stored at 3 40 Ê C.
Materials
The¯uorescein±boronic acid derivative,¯uor-escein±5-[thioureidyl-(3-phenylboronic acid)], was prepared and puri®ed as described previously. 14, 15 The product was diluted in a methanol±water mixture at a concentration of 20 mmol/L and stored at 4 Ê C. The assay buffer consisted of 100 mmol/L glycine (AnalaR; BDH, Poole, UK), 50 mmol/L magnesium chloride hexahydrate (AnalaR; BDH) and 0´01% sodium azide, adjusted to pH 8´5 by the addition of saturated sodium hydroxide. Calibration material was prepared from a pool of serum samples with a high concentration of total glycated serum protein. This was lyophilized in 2-mL amounts and kept at 4 Ê C for long-term storage (stable for > 2 years). For use in assays the lyophilized serum was reconstituted with distilled water and 10 200-mL aliquots were prepared and stored at 3 40 Ê C (stable for > 6 months). The pool was calibrated against the calibrant for the NBT assay (Boehringer Mannheim GmbH, Mannheim, Germany).
Methods
Fructosamine was measured using NBT dye, which is reduced to form a product that absorbs at 540 nm. 18 Backgrounds were subtracted by measuring absorbance at 700 nm. The assay was performed using fructosamine reagents (Boehringer) on an Olympus AU600 (Olympus Diagnostic Systems, London, UK) automated analyser. A 10-mL aliquot of serum was added to 180 mL of reagent and incubated at 37 Ê C for 5 min. The absorbance was then recorded at 540 and 700 nm. Sample concentrations were calculated from the absorbances of calibrant material.
The new¯uorescence quenching assay was as follows. A 10-mL aliquot of serum (calibrant or QC or sample) was pipetted in duplicate into 4´5-mL square polymethacrylate cuvettes (four clear sides; Elkay, Shrewsbury MA, USA). Ā uorescein±boronic acid solution (®nal concentration 100 nmol/L) was prepared by adding 0´5 mL of the 20 mmol/L¯uorescein±boronic acid solution to 100 mL of assay buffer; 4 mL of this solution was added to the serum using a repeater pipette. Additionally, the¯uorescein±boronic acid solution was added to two cuvettes without serum. The cuvettes were protected from light and left for 15 min at room temperature. Thē uorescence intensity (arbitrary units) was then read on a ®lter¯uorimeter (transmission peaks: l exˆ4 50 nm, l emˆ5 25 nm). 
Sample and QC concentrations were estimated by linear interpolation from a straight line drawn between the¯uorescence intensity of uorescent boronic acid solution with no sample
RESULTS
Fluorescence spectra
Fluorescence emission spectra (l exˆ4 85 nm, l emˆ5 00±600 nm; slits 5 nm/5 nm) of the¯uor-escein±boronic acid solution with and without sample addition were recorded on a Perkin-Elmer LS50B spectro¯uorimeter (Beacons®eld, UK). Three samples were chosen with a range of total glycated serum protein concentrations (190± 660 mmol/L). The¯uorescence was quenched on mixing with serum. The emission spectra gave the same maximumemission wavelength (517 nm) for all the above samples. The intensity of the emission decreased as the glycated protein concentration increased.
Reaction time
The time for the reaction between serum and thē urophore to give a steady¯uorescence intensity was > 14 min for samples with high and low total glycated serum protein concentrations.
Comparison with NBT method and assay performance
Serum samples (n=114) were assayed by the NBT reduction method and by the¯uorescence quenching method described above. Results were compared by linear regression, correlation and standard error of estimate. Fluorescence quench-ing=0´9426 0´034) NBT+25´02 (6 12´21),r=0´934, S y/x =45´47, n=114 (6 SD, standard deviation, in parentheses). The difference between the results for the¯uorescence quenching and NBT methods was plotted against the mean of the two results (Bland± Altman plot; 19 Fig. 2) . The reference range, which was determined from the results for 25 subjects (12 men, 13 women; age 15±65 years) with no history of diabetes, gave values with 95% con®dence limits of 220±304 mmol/L. Intra-and inter-assay precision pro®les are shown in Fig. 3 . Assay linearity was tested by diluting serum samples that had a high total glycated serum protein concentration in samples with a low total glycated serum protein concentration (Fig. 4) .
Effects of potential interfering substances
Samples showed less than 2´1% difference to base results with added glucose (up to 60 mmol/L), less than 9´7% difference with added bilirubin (up to 250 mmol/L) and less than 6´9% difference with added triglycerides (up to 50 mmol/L). Addition of haemoglobin (up to 9´0 g/L) with high glycation (11´7% HbA 1c ; Menarini Arkray HA-8140 HPLC, Florence, Italy) to plasma (298 mmol/L total glycated protein) showed less than 10% difference (2´7% at 2´0 g/L haemoglobin) to base result.
Effect of temperature on assays and storage of reagents
Twelve serum samples were assayed at 12, 21, 25
and 34 Ê C. All assay reagents, cuvettes and the ®lter¯uorimeter were brought up to the speci®ed A simple assay for total glycated serum protein 375
Ann Clin Biochem 2000: 37 FIGURE 2. Total glycated serum protein assays compared by Bland±Altman plot. 19 Mean difference (6 standard deviation, SD) is 5´5 (6 45´9 Aliquots of 20 mmol/L of¯uorescent boronic acid solution and assay buffer were stored at 4 Ê C. Assays performed before storage showed no signi®cant difference in results to assays performed after 20 weeks. Reagents stored at 37 Ê C gave no signi®cant difference in results after 4 weeks of storage.
A summary of the results and a comparison with those of the NBT assay are given in Table 1 .
DISCUSSION
The results given in this paper demonstrate that uorescein is quenched when bound to glycated proteins via a boronate ester (Fig. 1 ). This ®nding is comparable to the quenching of uorescein derivatives when bound covalently or immunologically to proteins. 20, 21 The¯uorescence quenching in all cases is probably due to the change of environment experienced by thē uorescein on binding to protein (leading to more non-radiative relaxation pathways) or to an interaction with tryptophan and tyrosine groups in the protein. 22 Boronic acid binding to cis-diols typically has an af®nity constant of 10 3 ±10 6 L/mol. 23 This can lead to dif®culties with separation assays unless a large excess of boronic acid groups is present (such as in a column). A non-separation method avoids the potential dif®culties and has the advantages of simplicity and rapidity.
Two attempts to develop non-separation assays utilizing boronic acids for the estimation of glycated serum protein have been described but have not been used routinely. One method, which claimed to be speci®c for glycated albumin in serum, used a dansyl boronic acid derivative. The dansyl boronic acid¯uorescence was markedly enhanced on binding to glycated albumin and the emission maximum wavelength dropped from 525 to 485 nm. 10 The enhancement was explained in terms of a secondary interaction between the dansyl group and albumin. Another assay utilized¯uorescence polarization to distinguish between the bound and free fractions of a¯uorescein±boronic acid derivative. 9 Fluorescence polarization measurements for a¯uorophore bound to protein show an increased intensity of emission parallel to the plane of polarization of the excitation light. By contrast, this paper describes a decrease in the total intensity of the light emission when thē uorescein±boronic acid is bound to protein. The measurement of intensity, as opposed to polarization, offers signi®cant advantages. The equipment is simpler and thus less expensive, and sample reading is quicker.
Results from the¯uorescence quenching assay correlated well with the NBT reduction method (Fig. 2) . Intra-assay precision was similar and inter-assay precision was better than with the NBT method (see Fig. 3 and Table 1 ). Both intraand inter-assayprecision were better than those of the recent enzyme-linked boronate immunoassay for glycated albumin (below 3´7% intra-assayand below 4´2% inter-assay). 13 A preliminary study of an assay reference range gave values that are about 20 mmol/L higher than the limits established for the fructosamine method (205± 285 mmol/L). 15 It was found that the¯uorescence can be read at any time after 14 min. This methodology is suitable for the manual assay of large batches of samples. By contrast, the reduction of NBT does not achieve steady absorbance and the time of reading is critical. On an automated analyser, samples are incubated at 37 Ê C for a set time (9 min) and then read for 1 min. 18 A manual version of the assay requires incubation at 37 Ê C for 15 min; absorbance is read at 10 and 15 min.
In common with other boronic acid methods, the addition of glucose showed very little interference in the assay. 24, 25 These low levels of interference are insigni®cant in clinical terms. It is to be expected that bilirubin will cause major interference with the assay as it is uorescent and has an emission maximum wavelength (l em, max ) close to that of¯uorescein (bilirubin 525 nm,¯uorescein 517 nm, both excited at 450 nm). However, even at the very high levels of bilirubin added to a sample of low total glycated serum concentration (279 mmol/ L), the increase in assay result is still only +9´7% (27´1 mmol/L) different from the base result. This low level of interference is probably due to three factors: samples are diluted 1 in 400 in the assay; the¯uorescein±boronic acid is at a relatively high concentration (100 nmol/L); and bilirubin has a very low quantum yield in aqueous solution. It is of note that the small observed increases in assay results correspond to a decrease in¯uorescence intensity of the samplē uorophore mixture. Therefore, it can be postulated that the bilirubin does not interfere by adding to the¯uorescence of the mixture but rather quenches interaction with the¯uorescein± boronic acid. The NBT method shows more interference from bilirubin (> 10% different from base result for concentrations greater than 100 mmol/L). 18 Addition of triglycerides (up to 50 mmol/L) to samples gave low levels of interference that are insigni®cant in clinical terms. The NBT method gives similar results up to 25 mmol/L triglyceride. Concentrations above 25 mmol/L have not been reported. 18 The addition of haemoglobin with high glycation produced interference that was signi®cantly less than that found in the NBT assay (> 10% for haemoglobin concentrationsgreater than 7´0 g/L, 0´1 mmol/L). 18 Levels greater than 1´0 g/L are not common in haemolysed serum or plasma samples, hence clinically signi®cant interference will not be encountered in practice.
Assays performed over a range of temperatures (12±34 Ê C) showed no signi®cant alteration in the results, thus enabling the method to be easily adopted without either laboratory airconditioning or temperature-controlled incubation equipment, although the effects of higher temperatures have not been tested. The NBT assay, by contrast, has to be carried out at 37 Ê C. Fluorophore and buffer stored at 4 Ê C for 20 weeks and 37 Ê C for 4 weeks showed no evidence of deterioration in performance, indicating that these reagents can be successfully used after storage at different temperatures. A purpose-built¯uorimeter suitable for this test is currently being developed. The instrument is expected to cost less than £500 (Skybio Ltd, UK). Reagents could be made available commercially at approximately £0´30 per test.
The¯uorescence quenching assay for total glycated serum protein described in this paper is simple and inexpensive, and demonstrates a high standard of performance. Such characteristics will become more important as the frequency of diabetes continues to rise dramatically, 26 particularly in the developing world.
